Compare Stocks: DMAC, ORIC, OMER, and VOR

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DMAC DiaMedica Therapeutics	$6.56 -2.8%	$6.93	$5.15 ▼ $10.42	$364M	0.98	127,833 shs	116,145 shs
OMER Omeros	$19.11 +1.3%	$13.31	$3.94 ▼ $19.65	$1.37B	2.6	2.45 million shs	1.17 million shs
ORIC Oric Pharmaceuticals	$12.74 -3.0%	$12.16	$7.23 ▼ $14.93	$1.36B	1	1.09 million shs	916,440 shs
VOR Vor Biopharma	$24.24 -2.1%	$21.10	$6.50 ▼ $49.95	$1.46B	1.71	739,924 shs	538,761 shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DMAC DiaMedica Therapeutics	-2.81%	-2.81%	0.00%	+16.31%	+23.77%
OMER Omeros	+1.33%	-0.73%	+47.68%	+95.20%	+357.18%
ORIC Oric Pharmaceuticals	-2.97%	-7.28%	-5.42%	+69.87%	+20.19%
VOR Vor Biopharma	-2.10%	+3.02%	+8.94%	+84.19%	-39.40%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DMAC DiaMedica Therapeutics	$6.56 -2.8%	$6.93	$5.15 ▼ $10.42	$364M	0.98	127,833 shs	116,145 shs
OMER Omeros	$19.11 +1.3%	$13.31	$3.94 ▼ $19.65	$1.37B	2.6	2.45 million shs	1.17 million shs
ORIC Oric Pharmaceuticals	$12.74 -3.0%	$12.16	$7.23 ▼ $14.93	$1.36B	1	1.09 million shs	916,440 shs
VOR Vor Biopharma	$24.24 -2.1%	$21.10	$6.50 ▼ $49.95	$1.46B	1.71	739,924 shs	538,761 shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DMAC DiaMedica Therapeutics	-2.81%	-2.81%	0.00%	+16.31%	+23.77%
OMER Omeros	+1.33%	-0.73%	+47.68%	+95.20%	+357.18%
ORIC Oric Pharmaceuticals	-2.97%	-7.28%	-5.42%	+69.87%	+20.19%
VOR Vor Biopharma	-2.10%	+3.02%	+8.94%	+84.19%	-39.40%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
DMAC DiaMedica Therapeutics	2.60	Moderate Buy	$12.00	82.93% Upside
OMER Omeros	2.67	Moderate Buy	$38.00	98.85% Upside
ORIC Oric Pharmaceuticals	2.79	Moderate Buy	$19.60	53.85% Upside
VOR Vor Biopharma	2.82	Moderate Buy	$43.38	78.94% Upside

Current Analyst Ratings Breakdown

Latest DMAC, ORIC, OMER, and VOR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/12/2026	VOR Vor Biopharma	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Neutral	$18.00 ➝ $27.00
8/11/2026	VOR Vor Biopharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (D-) ➝ Sell (D+)
8/11/2026	DMAC DiaMedica Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$12.00
8/10/2026	ORIC Oric Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$25.00 ➝ $27.00
8/5/2026	OMER Omeros	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (D+) ➝ Hold (C-)
7/27/2026	OMER Omeros	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
7/17/2026	DMAC DiaMedica Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/17/2026	ORIC Oric Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/13/2026	OMER Omeros	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
6/30/2026	VOR Vor Biopharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
6/26/2026	OMER Omeros	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$40.00 ➝ $33.00

(Data available from 9/4/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
DMAC DiaMedica Therapeutics	N/A	N/A	N/A	N/A	$0.71 per share	N/A
OMER Omeros	N/A	N/A	$1.90 per share	10.08	($0.71) per share	N/A
ORIC Oric Pharmaceuticals	N/A	N/A	N/A	N/A	$3.68 per share	N/A
VOR Vor Biopharma	N/A	N/A	N/A	N/A	N/A	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
DMAC DiaMedica Therapeutics	-$32.77M	-$0.72	N/A	N/A	N/A	N/A	-77.76%	-69.43%	11/11/2026 (Estimated)
OMER Omeros	-$3.35M	$1.28	14.93	16.91	N/A	N/A	-164.92%	69.41%	11/12/2026 (Estimated)
ORIC Oric Pharmaceuticals	-$129.47M	-$1.35	N/A	N/A	N/A	N/A	-35.35%	-33.39%	11/12/2026 (Estimated)
VOR Vor Biopharma	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Latest DMAC, ORIC, OMER, and VOR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2026	Q2 2026	OMER Omeros	-$0.2683	$0.02	+$0.2883	$0.15	$12.69 million	$28.53 million
8/11/2026	Q2 2026	VOR Vor Biopharma	-$0.69	-$0.80	-$0.11	-$1.16	N/A	N/A
8/10/2026	Q2 2026	DMAC DiaMedica Therapeutics	-$0.2009	-$0.19	+$0.0109	-$0.19	$13.50 million	N/A
8/3/2026	Q2 2026	ORIC Oric Pharmaceuticals	-$0.3594	-$0.38	-$0.0207	-$0.38	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
DMAC DiaMedica Therapeutics	N/A	N/A	N/A	N/A	N/A
OMER Omeros	N/A	N/A	N/A	N/A	N/A
ORIC Oric Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
VOR Vor Biopharma	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
DMAC DiaMedica Therapeutics	N/A	6.72	6.72
OMER Omeros	N/A	1.95	1.94
ORIC Oric Pharmaceuticals	N/A	13.19	13.19
VOR Vor Biopharma	N/A	N/A	N/A

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
DMAC DiaMedica Therapeutics	10.12%
OMER Omeros	48.79%
ORIC Oric Pharmaceuticals	95.05%
VOR Vor Biopharma	97.29%

Insider Ownership

Company	Insider Ownership
DMAC DiaMedica Therapeutics	5.00%
OMER Omeros	10.50%
ORIC Oric Pharmaceuticals	5.70%
VOR Vor Biopharma	0.27%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
DMAC DiaMedica Therapeutics	20	53.93 million	51.23 million	Optionable
OMER Omeros	210	72.39 million	64.79 million	Optionable
ORIC Oric Pharmaceuticals	80	103.65 million	97.75 million	Optionable
VOR Vor Biopharma	140	59.16 million	59.00 million	N/A

DMAC, ORIC, OMER, and VOR Headlines

Recent News About These Companies

Braidwell LP Has $10.55 Million Stake in Vor Biopharma Inc. $VOR

September 3 at 4:39 AM | marketbeat.com

Bank of America Corp DE Has $2.01 Million Stock Holdings in Vor Biopharma Inc. $VOR

September 3 at 3:12 AM | marketbeat.com

Vor Biopharma Inc. (NASDAQ:VOR) Receives Consensus Recommendation of "Moderate Buy" from Analysts

September 3 at 2:44 AM | americanbankingnews.com

Vor Biopharma Inc. (NASDAQ:VOR) Given Average Recommendation of "Moderate Buy" by Brokerages

September 3 at 2:43 AM | marketbeat.com

Vor Biopharma (NASDAQ:VOR) Stock Price Up 6.2% - Time to Buy?

September 2 at 11:59 AM | marketbeat.com

Vor Bio To Participate in Upcoming September Conferences

September 1 at 8:00 AM | globenewswire.com

Wall Street Zen Upgrades Vor Biopharma (NASDAQ:VOR) to Hold

August 15, 2026 | marketbeat.com

Q3 EPS Estimates for Vor Biopharma Reduced by HC Wainwright

August 14, 2026 | marketbeat.com

Vor Biopharma FY2030 EPS Forecast Reduced by HC Wainwright

August 13, 2026 | marketbeat.com

Wedbush Issues Positive Forecast for Vor Biopharma (NASDAQ:VOR) Stock Price

August 12, 2026 | marketbeat.com

Vor Biopharma (NASDAQ:VOR) Trading Down 6.5% on Disappointing Earnings

August 12, 2026 | marketbeat.com

Vor Biopharma Shares Drop After Q2 Results

August 11, 2026 | finance.yahoo.com

Vor Biopharma (NASDAQ:VOR) Posts Earnings Results

August 11, 2026 | marketbeat.com

Vor Biopharma: Vor Bio Reports Second Quarter 2026 Financial Results and Provides Corporate Update

August 11, 2026 | finanznachrichten.de

Renaissance Technologies LLC Makes New $2.30 Million Investment in Vor Biopharma Inc. $VOR

August 11, 2026 | marketbeat.com

Vor Biopharma Inc. (NASDAQ:VOR) Receives Consensus Rating of "Moderate Buy" from Analysts

August 9, 2026 | marketbeat.com

Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

August 3, 2026 | globenewswire.com

Vor Biopharma: Vor Bio Appoints David Zaccardelli to Board of Directors

July 8, 2026 | finanznachrichten.de

Vor Bio Appoints David Zaccardelli to Board of Directors

July 7, 2026 | globenewswire.com

Vor Biopharma: A Financed Autoimmune Pivot With More Substance Than The Market Realizes

July 7, 2026 | seekingalpha.com

Vor Biopharma Stock Short Interest Report | NASDAQ:VOR | Benzinga

July 3, 2026 | benzinga.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

DMAC, ORIC, OMER, and VOR Company Descriptions

DiaMedica Therapeutics NASDAQ:DMAC

$6.56 -0.19 (-2.81%)

As of 09/3/2026 04:00 PM Eastern

DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase II/III trials for the treatment of acute ischemic stroke, as well as that is in Phase 2 to treat cardio-renal disease. The company also develops DM300, which is in preclinical stage for the treatment of severe inflammatory diseases. In addition, it develops treatment for neurological disease. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.

Omeros NASDAQ:OMER

$19.11 +0.25 (+1.33%)

As of 09/3/2026 04:00 PM Eastern

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19. It also develops OMS1029 that is in phase I clinical trials for long-acting second-generation antibody targeting lectin pathway disorders; OMS906 that has completed phase II clinical trials for Paroxysmal nocturnal hemoglobinuria, complement 3 glomerulopathy, and other alternative pathway disorders; and OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders. In addition, the company's products under preclinical development comprise MASP-2, a pro-inflammatory protein target for the treatment of lectin pathway disorders; MASP-3 small-molecule inhibitors for alternative pathway disorders; and Adoptive T-Cell and Chimeric Antigen Receptor (CAR) T-Cell Therapies and Immunomodulators/Immunotoxins/Cancer Vaccines for the treatment of various cancers. Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington.

Oric Pharmaceuticals NASDAQ:ORIC

$12.74 -0.39 (-2.97%)

As of 09/3/2026 04:00 PM Eastern

ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, which is designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study; and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, currently under Phase 1b study, being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens. The company is also developing multiple discovery stage precision medicines targeting other cancer resistance mechanisms, including ORIC-613, an orally bioavailable, highly selective inhibitor of PLK4, in preclinical studies for the treatment of breast cancers. It has a license and collaboration agreement with Voronoi Inc.; a license agreement with Mirati Therapeutics, Inc.; and clinical development collaboration agreement with Pfizer Inc. The company was incorporated in 2014 and is headquartered in South San Francisco, California.

Vor Biopharma NASDAQ:VOR

$24.24 -0.52 (-2.10%)

As of 09/3/2026 04:00 PM Eastern

Vor Biopharma, Inc., a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. The company's VOR33 eHSCs lacks CD33, a protein that is expressed by AML blood cancer cells. The company's eHSCs targeted therapies, such as CAR-Ts, bispecific antibodies, and antibody-drug conjugates provide treatment for blood cancers. Vor Biopharma, Inc. has a collaboration agreement with Akron BioProducts to develop and manufacture cGMP nucleases. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest DMAC, ORIC, OMER, and VOR Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest DMAC, ORIC, OMER, and VOR Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

DMAC, ORIC, OMER, and VOR Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

DMAC, ORIC, OMER, and VOR Company Descriptions

DiaMedica Therapeutics NASDAQ:DMAC

Omeros NASDAQ:OMER

Oric Pharmaceuticals NASDAQ:ORIC

Vor Biopharma NASDAQ:VOR

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest DMAC, ORIC, OMER, and VOR Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest DMAC, ORIC, OMER, and VOR Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

DMAC, ORIC, OMER, and VOR Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

DMAC, ORIC, OMER, and VOR Company Descriptions

DiaMedica Therapeutics NASDAQ:DMAC

Omeros NASDAQ:OMER

Oric Pharmaceuticals NASDAQ:ORIC

Vor Biopharma NASDAQ:VOR

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools